Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor.
- Resource Type
- Academic Journal
- Authors
- Derkus B; Department of Chemistry, Ankara University, Tandogan, Ankara 06100, Turkey.; Acar Bozkurt P; Department of Chemistry, Ankara University, Tandogan, Ankara 06100, Turkey.; Tulu M; Department of Chemistry, Yildiz Technical University, Esenler, Istanbul 34220, Turkey.; Emregul KC; Department of Chemistry, Ankara University, Tandogan, Ankara 06100, Turkey.; Yucesan C; Department of Neurology, Medical School, Ankara University, Ibni Sina Hospital, Sihhiye, Ankara 06100, Turkey.; Emregul E; Department of Chemistry, Ankara University, Tandogan, Ankara 06100, Turkey. Electronic address: eemregul@yahoo.com.
- Source
- Publisher: Elsevier Advanced Technology Country of Publication: England NLM ID: 9001289 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4235 (Electronic) Linking ISSN: 09565663 NLM ISO Abbreviation: Biosens Bioelectron Subsets: MEDLINE
- Subject
- Language
- English
This study was aimed at the development of an immunosensor for the simultaneous quantification of Myelin Basic Protein (MBP) and Tau proteins in cerebrospinal fluid (CSF) and serum, obtained from Multiple Sclerosis (MS) patients. The newly developed GO/pPG/anti-MBP/anti-Tau nanoimmunosensor has been established by immobilization of MBP and Tau antibodies. The newly developed nanoimmunosensor was tested, optimized and characterized using differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The developed nanoimmunosensor was seen to have detection limits of 0.30nM for MBP and 0.15nM for Tau proteins which were sufficient for the levels to be analysed in neuro-clinic. The clinical study performed using CSF and serum of MS patients showed that the designed nanoimmunosensor was capable of detecting the proteins properly, that were essentially proven by ELISA.
(Copyright © 2016 Elsevier B.V. All rights reserved.)